Congcong Liu

Shenzhen, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications

A visible assay for evaluating the inhibitory activity of drug and antibody against HBV infection.

A visible assay for evaluating the inhibitory activity of drug and antibody against HBV infection.

Journal: Microbiology spectrum
Published: March 11, 2026

A SARS-CoV-2 variant-induced NTD-targeting antibody enhances viral infection via a distinctive binding mode.

A SARS-CoV-2 variant-induced NTD-targeting antibody enhances viral infection via a distinctive binding mode.

Journal: PLoS pathogens
Published: May 26, 2025

Structure and function of an unusual R452-dependent monoclonal antibody against SARS-CoV-2.

Structure and function of an unusual R452-dependent monoclonal antibody against SARS-CoV-2.

Journal: Journal of virology
Published: April 08, 2025

Structure and function of a pair of non-competing monoclonal antibodies against Langya henipavirus attachment glycoprotein.

Structure and function of a pair of non-competing monoclonal antibodies against Langya henipavirus attachment glycoprotein.

Journal: Cell reports
Published: March 23, 2025

Structurally conserved human anti-A35 antibodies protect mice and macaques from mpox virus infection.

Structurally conserved human anti-A35 antibodies protect mice and macaques from mpox virus infection.

Journal: Cell
Published: March 01, 2025

The characterization and structural basis of a human broadly binding antibody to HBV core protein.

The characterization and structural basis of a human broadly binding antibody to HBV core protein.

Journal: Journal of virology
Published: November 27, 2024

NIEAs elicited by wild-type SARS-CoV-2 primary infection fail to enhance the infectivity of Omicron variants.

NIEAs elicited by wild-type SARS-CoV-2 primary infection fail to enhance the infectivity of Omicron variants.

Journal: Virology journal
Published: November 23, 2024

A distinctive IGHV3-66 SARS-CoV-2 neutralizing antibody elicited by primary infection with an Omicron variant.

A distinctive IGHV3-66 SARS-CoV-2 neutralizing antibody elicited by primary infection with an Omicron variant.

Journal: Structure (London, England : 1993)
Published: November 11, 2024

Rapid clonal expansion and somatic hypermutation contribute to the fate of SARS-CoV-2 broadly neutralizing antibodies.

Rapid clonal expansion and somatic hypermutation contribute to the fate of SARS-CoV-2 broadly neutralizing antibodies.

Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: March 22, 2024

Omicron BQ.1.1 and XBB.1 unprecedentedly escape broadly neutralizing antibodies elicited by prototype vaccination.

Omicron BQ.1.1 and XBB.1 unprecedentedly escape broadly neutralizing antibodies elicited by prototype vaccination.

Journal: Cell reports
Published: December 01, 2022
Showing 1-10 of 10

Last Updated: 09/26/2026